Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

被引:99
作者
Romano, Gaetano [1 ]
Giordano, Antonio [1 ,2 ]
机构
[1] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA
[2] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy
关键词
cdk9; cyclins T; cyclin K; carcinogenesis; cardiac hypertrophy;
D O I
10.4161/cc.7.23.7122
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclin-dependent kinase 9 (Cdk9) is a cdc2-like serine/threonine kinase. The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1, cyclin T2a, cyclin T2b and cyclin K. The association between Cdk9 and one of its cyclin partners forms a heterodimer, which is the main component of the positive transcription elongation factor (P-TEFb). The latter stabilizes the elongation process of RNA polymerase II (polII) transcripts. Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation. Incidentally, the P-TEFb that contains the heterodimer Cdk9-cyclin T1 is also critical for HIV-1 and HIV-2 replication in human cells. A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy. On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose: (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.
引用
收藏
页码:3664 / 3668
页数:5
相关论文
共 83 条
[1]   Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9 [J].
Baek, Kyuwon ;
Brown, Raymond S. ;
Birrane, Gabriel ;
Ladias, John A. A. .
JOURNAL OF MOLECULAR BIOLOGY, 2007, 366 (02) :563-573
[2]  
Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.0.CO
[3]  
2-R
[4]  
Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO
[5]  
2-1
[6]  
Balk S., 2008, NUCL RECEPT SIGNAL, V6, pe001, DOI [DOI 10.1621/NRS.060016, DOI 10.1621/NRS.06001]
[7]   EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5 [J].
Bark-Jones, SJ ;
Webb, HM ;
West, MJ .
ONCOGENE, 2006, 25 (12) :1775-1785
[8]   CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation [J].
Bellan, C ;
De Falco, G ;
Lazzi, S ;
Micheli, R ;
Vicidomini, S ;
Schürfeld, K ;
Amato, T ;
Palumbo, A ;
Bagella, L ;
Sabattini, E ;
Bartolommei, S ;
Hummel, M ;
Pileri, S ;
Tosi, P ;
Leoncini, L ;
Giordano, A .
JOURNAL OF PATHOLOGY, 2004, 203 (04) :946-952
[9]   Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases [J].
Bettayeb, Karima ;
Tirado, Oscar M. ;
Marionneau-Lambot, Severine ;
Ferandin, Yoan ;
Lozach, Olivier ;
Morris, Jonathan C. ;
Mateo-Lozano, Silvia ;
Drueckes, Peter ;
Schaechtele, Christoph ;
Kubbutat, Michael H. G. ;
Liger, Francois ;
Marquet, Bernard ;
Joseph, Benoit ;
Echalier, Aude ;
Endicott, Jane A. ;
Notario, Vicente ;
Meijer, Laurent .
CANCER RESEARCH, 2007, 67 (17) :8325-8334
[10]   The CDK inhibitors: potential targets for therapeutic stem cell manipulations? [J].
Boyer, M. J. ;
Cheng, T. .
GENE THERAPY, 2008, 15 (02) :117-125